S.lugdunensis is the Sammy Sosa of the SOSA 💥

I'm the only one from the group on BlueSky!?? 🤔 Anyway, this one was 95% Mackenzie Keintz, so particular shout-out to her!

Depending on underlying indication and acuity, I'd start with AmB, or an AmB combo. One other FDA-approved option you could consider is ibrexafungerp. The only trial for IC I know of used 750mg BID x 2d, then 750mg daily through EOT (~2wks in the study). Experience outside VVC is very limited.

Welcome! The positives outweigh the current tradeoffs for the most of us. Really enjoy driving my Ioniq 5.

There definitely is, we are apparently just incapable of choosing it. Pharmacist-on-pharmacist crime, and this unfortunately isn't the only example... ACPE, MPJE, etc. A big loss to trainees when paperwork burnout robs them of superlative mentorship those like you are otherwise eager to provide.

Not enough! Pseudo less often mainly because the data are very limited for more complicated cystitis or pyelo where those are more common, but underutilized vs OPAT for Enterobacterales where resistance precludes or complicates oral therapy.

That's 1-2 articles PER PATIENT, right? I thought so... just doesn't make sense otherwise. Thanks! 😉

Thanks very much, these are endlessly helpful for recreating the community!